A new test might help to decrease the 80% of oesophageal tumours that are not shrunk before surgery by standard chemotherapy. — TNS
Researchers at Queen’s University Belfast (Queen’s) in the United Kingdom have developed a test that could radically improve the lives of people with oesophageal cancer through a personalised medicine approach.
The researchers at Queen’s and the University of Cambridge, UK, in partnership with the stratified medicine company Almac Diagnostic Services, have validated a test that, for the first time, could enable clinicians to decide the most appropriate chemotherapy for early stage oesophageal cancer.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
